Clinical Trial: NCT03899792
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Eli Lilly and Company |
| Information Provided By: | Eli Lilly and Company |
| Last Update Posted: | 2026-01-06 |
Study Overview
Brief Summary
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
Official Title
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
Conditions
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
Intervention / Treatment
- Drug: Selpercatinib
Other Study ID Numbers
- 17493
- J2G-OX-JZJJ
- LOXO-RET-18036
- 2019-000212-28
- 2019
Start Date (Actual)
2019-06-13
Primary Completion Date (Actual)
2024-11-08
Study Completion Date (Estimated)
2029-05
Enrollment (Actual)
36
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | Eli Lilly and Company |
| Information Provided By: | Eli Lilly and Company |
| Last Update Posted: | 2026-01-06 |
Study Overview
Brief Summary
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
Official Title
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
Conditions
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
Intervention / Treatment
- Drug: Selpercatinib
Other Study ID Numbers
- 17493
- J2G-OX-JZJJ
- LOXO-RET-18036
- 2019-000212-28
- 2019
Start Date (Actual)
2019-06-13
Primary Completion Date (Actual)
2024-11-08
Study Completion Date (Estimated)
2029-05
Enrollment (Actual)
36
Study Type
Interventional
Phase
Phase 1, Phase 2